ICH Harmonised Tripartite Guideline

Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Tablet Friability General Chapter
Q4B Annex 9(R1)

Current Step 4 version
dated 27 September 2010

This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.
# Q4B Annex 9(R1)

## Document History

<table>
<thead>
<tr>
<th>Code</th>
<th>History</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4B Annex 9</td>
<td>Approval by the Steering Committee under <em>Step 2</em> and release for public consultation.</td>
<td>11 June 2009</td>
</tr>
<tr>
<td>Q4B Annex 9</td>
<td>Approval by the Steering Committee under <em>Step 4</em> and recommendation for adoption to the three ICH regulatory bodies.</td>
<td>29 October 2009</td>
</tr>
</tbody>
</table>

## Current *Step 4* version

| Q4B Annex 9(R1) | Integration of the Health Canada Interchangeability Statement under Section 4.5 after approval by the Steering Committee. | 27 September 2010 |
Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Tablet Friability General Chapter

ICH Harmonised Tripartite Guideline

Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 29 October 2009, this guideline is recommended for adoption to the three regulatory parties to ICH

(This annex was revised -R1- to include the Interchangeability Statement from Health Canada on September 27, 2010)

Table of Contents

1. Introduction ........................................................................................................................................ 1
2. Q4B Outcome ...................................................................................................................................... 1
   2.1 Analytical Procedures ................................................................................................................... 1
   2.2 Acceptance Criteria .................................................................................................................... 1
3. Timing of Annex Implementation .................................................................................................... 1
4. Considerations for Implementation .................................................................................................. 1
   4.1 General Consideration ................................................................................................................ 1
   4.2 FDA Consideration .................................................................................................................... 1
   4.3 EU Consideration ...................................................................................................................... 2
   4.4 MHLW Consideration ................................................................................................................ 2
   4.5 Health Canada Consideration .................................................................................................. 2
5. References Used for the Q4B Evaluation ......................................................................................... 2
EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS
ON TABLET FRIABILITY GENERAL CHAPTER
Q4B ANNEX 9(R1)

1. INTRODUCTION

This annex is the result of the Q4B process for the Tablet Friability General Chapter. The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).

2. Q4B OUTCOME

2.1 Analytical Procedures

The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the analytical procedures described in the official pharmacopoeial texts, Ph.Eur. 2.9.7. Friability of Uncoated Tablets, JP General Information 26. Tablet Friability Test, and USP <1216> Tablet Friability, can be used as interchangeable in the ICH regions.

2.2 Acceptance Criteria

For interchangeability, the loss of mass for a single determination should be not more than 1.0 percent, unless otherwise specified in the dossier. When three determinations are conducted, then the mean loss of mass for the three determinations should be not more than 1.0 percent, unless otherwise specified in the dossier.

3. TIMING OF ANNEX IMPLEMENTATION

When this annex is implemented (incorporated into the regulatory process at ICH Step 5) in a region, it can be used in that region. Timing might differ for each region.

4. CONSIDERATIONS FOR IMPLEMENTATION

4.1 General Consideration

When sponsors or manufacturers change their existing methods to the implemented Q4B-evaluated pharmacopoeial texts that are referenced in Section 2.1 of this annex, any change notification, variation, and/or prior approval procedures should be handled in accordance with established regional regulatory mechanisms pertaining to compendial changes.

4.2 FDA Consideration

Based on the recommendation above, and with reference to the conditions set forth in this annex, the pharmacopoeial texts referenced in Section 2.1 of this annex can be considered
interchangeable. However, FDA might request that a company demonstrate that the chosen
method is acceptable and suitable for a specific material or product, irrespective of the
origin of the method.

4.3 EU Consideration
For the European Union, regulatory authorities can accept the reference in a marketing
authorisation application, renewal or variation application citing the use of the
corresponding text from another pharmacopoeia as referenced in Section 2.1, in accordance
with the conditions set out in this annex, as fulfilling the requirements for compliance with
the Ph. Eur. Chapter 2.9.7. on the basis of the declaration of interchangeability made above.

4.4 MHLW Consideration
The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as
interchangeable in accordance with the conditions set out in this annex. Details of
implementation requirements will be provided in the notification by MHLW when this
annex is implemented.

4.5 Health Canada Consideration
In Canada, any of the pharmacopoeial texts cited in section 2.1 of this annex and used in
accordance with the conditions set out in this annex can be considered interchangeable.

5. REFERENCES USED FOR THE Q4B EVALUATION

5.1 The PDG Stage 5B sign-off document: *Japanese Pharmacopoeial Forum*, Volume 14,
number 1 (March 2005).

5.2 The pharmacopoeial references for Tablet Friability General Chapter for this annex
are:

5.2.1 *European Pharmacopoeia* (Ph. Eur.): Supplement 6.6 (published June 2009,
official January 2010), Friability of Uncoated Tablets (reference 01/2010:20907);

Friability Test as it appears in the JP Fifteenth Edition (March 31, 2006, The
Ministry of Health, Labour and Welfare Ministerial Notification No. 285),
officially updated by errata published by MHLW at
on November 5, 2008;

5.2.3 *United States Pharmacopeia* (USP): <1216> Tablet Friability, official in USP
32, May 1, 2009.